Innorna Nominated for 2026 Prix Galien USA Best Startup Award

Innorna, a clinical-stage biotechnology company focused on developing RNA therapeutics, announced its nomination for the 2026 Prix Galien USA Best Startup Award. This recognition highlights the company's progress in the field of medical technology.

The Prix Galien Award is widely regarded as a prestigious honor in the life sciences, celebrating innovations that improve patient outcomes and quality of life. The annual ceremony convenes leading researchers, industry executives, and healthcare professionals.

Innorna's work centers on leveraging RNA technology to create novel treatment options. Its nomination suggests a strong potential to bring new and effective therapies to market. The competition for this award is intense, making the nomination itself a significant achievement.

The award ceremony is scheduled to take place in the United States. Winners will be announced later this year, representing the latest breakthroughs in medical science and healthcare.